LifeMD, Inc. (LFMD)
| Market Cap | 703.23M |
| Revenue (ttm) | 28.34M |
| Net Income (ttm) | -30.61M |
| Shares Out | 14.67M |
| EPS (ttm) | -2.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $21.94 |
| Previous Close | $20.51 |
| Change ($) | 1.43 |
| Change (%) | 6.97% |
| Day's Open | 20.72 |
| Day's Range | 19.62 - 29.40 |
| Day's Volume | 766,666 |
| 52-Week Range | 5.81 - 33.02 |
News
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the mark...
About LFMD
Conversion Labs operates as a telemedicine company with a portfolio of online direct-to-consumer brands. The company combines virtual medical treatment with prescription medications and over-the-counter products. Its network of physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. Its brand portfolio comprises of brands targeting market segments, such as hair loss, immune health, men's health, and disaster preparedness. The company was formerly known as Immudyne, Inc. and changed its name to Conver... [Read more...]
| Industry Pharmaceutical Retailers | Founded 1994 |
| CEO Justin Schreiber | Employees 26 |
| Stock Exchange NASDAQ | Ticker Symbol LFMD |
Financial Performance
In 2019, LifeMD's revenue was $12.47 million, an increase of 49.79% compared to the previous year's $8.32 million. Losses were -$3.14 million, 152.8% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for LifeMD stock is "Strong Buy" and the 12-month stock price forecast is 37.50.